Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-PROTECT: Hydroxychloroquine +/- Azithromycin for COVID-19
NCT04349592Completed
- Sponsor
- Hamad Medical Corporation
- Start
- Apr 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Hamad Medical Corporation. Primary endpoint: Proportion of virologically cured (PCR-negative status) at Day 6. Started Apr 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04349592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349592.